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Abstract
Background
Psoriasis is a common inflammatory skin disease that has been reported to be associated
with obesity. We aimed to investigate a possible causal relationship between body mass
index (BMI) and psoriasis.
Methods and findings
Following a review of published epidemiological evidence of the association between obe-
sity and psoriasis, mendelian randomization (MR) was used to test for a causal relationship
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with BMI. We used a genetic instrument comprising 97 single-nucleotide polymorphisms
(SNPs) associated with BMI as a proxy for BMI (expected to be much less confounded than
measured BMI). One-sample MR was conducted using individual-level data (396,495 indi-
viduals) from the UK Biobank and the Nord-Trøndelag Health Study (HUNT), Norway. Two-
sample MR was performed with summary-level data (356,926 individuals) from published
BMI and psoriasis genome-wide association studies (GWASs). The one-sample and two-
sample MR estimates were meta-analysed using a fixed-effect model. To test for a potential
reverse causal effect, MR analysis with genetic instruments comprising variants from recent
genome-wide analyses for psoriasis were used to test whether genetic risk for this skin dis-
ease has a causal effect on BMI.
Published observational data showed an association of higher BMI with psoriasis. A
mean difference in BMI of 1.26 kg/m2 (95% CI 1.02–1.51) between psoriasis cases and con-
trols was observed in adults, while a 1.55 kg/m2 mean difference (95% CI 1.13–1.98) was
observed in children. The observational association was confirmed in UK Biobank and
HUNT data sets. Overall, a 1 kg/m2 increase in BMI was associated with 4% higher odds of
psoriasis (meta-analysis odds ratio [OR] = 1.04; 95% CI 1.03–1.04; P = 1.73 × 10−60). MR
analyses provided evidence that higher BMI causally increases the odds of psoriasis (by 9%
per 1 unit increase in BMI; OR = 1.09 (1.06–1.12) per 1 kg/m2; P = 4.67 × 10−9). In contrast,
MR estimates gave little support to a possible causal effect of psoriasis genetic risk on BMI
(0.004 kg/m2 change in BMI per doubling odds of psoriasis (−0.003 to 0.011). Limitations of
our study include possible misreporting of psoriasis by patients, as well as potential misdiag-
nosis by clinicians. In addition, there is also limited ethnic variation in the cohorts studied.
Conclusions
Our study, using genetic variants as instrumental variables for BMI, provides evidence that
higher BMI leads to a higher risk of psoriasis. This supports the prioritization of therapies
and lifestyle interventions aimed at controlling weight for the prevention or treatment of this
common skin disease. Mechanistic studies are required to improve understanding of this
relationship.
Author summary
Why was this study done?
• Psoriasis is a common inflammatory skin disease that has been reported to be associated
with obesity. However, the direction of causality has not been established.
• Understanding the causal relationship could inform the management or prevention of
disease.
Causal impact of body mass index on psoriasis
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What did the researchers do and find?
• A mendelian randomization (MR) approach was used to investigate the causal relation-
ship between higher body mass index (BMI) and psoriasis.
• Our analysis included data for a total of 753,421 individuals from two of the largest pop-
ulation-based studies available as well as published genome-wide association studies
(GWASs).
• We found evidence that higher BMI causally increases the risk of psoriasis, supporting
observational reports in previous literature.
• Conversely, there was no evidence to support a causal effect of psoriasis genetic risk
upon BMI.
What do these findings mean?
• Our findings suggest that obesity contributes to the pathogenesis of psoriasis, and high-
light possible mechanistic relationships.
• If our findings regarding genetically influenced BMI can be extended to elevated BMI
that is amenable to modification by diet or behavior, then they could carry health
implications.
• Further work will be required to determine the effect of a short-term intervention
aimed at reducing BMI upon psoriasis patients after disease onset, ideally within a clini-
cal trial setting.
Introduction
Psoriasis is a common inflammatory skin disorder that is characterized by erythematous scaly
plaques; severe disease is associated with significant impairment in physical and mental health
[1]. Psoriasis affects approximately 2% of people within European populations [2], with higher
prevalence estimates in northern regions of Europe [3]. The prevalence of disease has also
been found to be increasing [4].
Obesity has become one of the leading health issues of the 21st century, with over one-quar-
ter of the United Kingdom population now obese and similarly high obesity levels in many
other parts of the world [5]. In addition to clear links of obesity to diabetes and hypertension,
observational evidence from epidemiological studies has suggested a relationship between
increased weight and psoriasis [6]. Furthermore, a small number of weight loss interventions
have been shown to improve psoriasis and increase responsiveness to treatment [7–9]. Hypo-
thetically, obesity could promote skin inflammation, or vice versa [10], but skin disease can
also lead to a reduced participation in physical activity, resulting in weight gain. A clearer
understanding of the cutaneous and systemic metabolic effects associated with obesity and
psoriasis is an essential prerequisite to define treatment and prevention strategies for these
prevalent public health issues.
Causality can be investigated with mendelian randomization (MR), which uses genetic vari-
ants to, in effect, randomly allocate individuals to groups based on genotype (analogous to a
Causal impact of body mass index on psoriasis
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randomized trial) [11]. At conception, genetic variants are expected to be randomly allocated
from parents to offspring. Therefore, confounding and reverse causation, common limitations
of observational studies, can be avoided by using genetic variants as instrumental variables to
estimate the causal effect of a risk factor upon an outcome of interest [11–13]. Genome-wide
association studies (GWASs) of body mass index (BMI) in the Genetic Investigation of
Anthropometric Traits (GIANT) consortium have identified 97 loci (accounting for 2.7% of
the variance of this trait) and made full summary statistics available [14] (a recent study has
increased this to 716 loci, explaining 5.0% of the variance [15]). GWAS summary statistics for
psoriasis are also available, for which 63 risk loci have been identified [16]. This work has pro-
vided powerful data with which to perform MR analyses [12].
In this study, we first reviewed the literature reporting observational evidence for associa-
tions between BMI and psoriasis and extended the observational associations in two large,
population-based studies. We then applied MR to test for evidence of causality, strength of
association, and the direction of causality between BMI and psoriasis.
Methods
Literature review and meta-analysis
We searched for published studies that compare the weight or overweight or obesity rates
between individuals with psoriasis and healthy controls. All studies identified in a PubMed
search were considered for review. PubMed was searched on July 8, 2016 with the terms
“psoriasis AND (obesity OR overweight OR BMI).” The inclusion criteria were as follows: an
operationalized definition of psoriasis (any definition was accepted, including psoriatic
arthritis), inclusion of cases meeting this definition of psoriasis plus a control group without
psoriasis, and presentation of data for a BMI-related trait within the psoriasis and control
groups. Studies were excluded if they did not present data for both groups, if they did not
present usable data in the paper, if they matched individuals with psoriasis and controls on
BMI, or if cases and controls were both drawn from a disease subpopulation. We did not
exclude studies in which participants may have incidental comorbidities. We extracted the
location of the study, the study name (if applicable), age of the study population, features of
the control group (e.g., if participants were drawn from another dermatological population),
the type of study, how psoriasis was determined (if it was current, recent, or lifetime disease),
the covariates used in the analysis, and the definition of overweight and obesity used by the
study. All data pertaining to weight and psoriasis were extracted, and a meta-analysis was
performed of the definition with the most available data (mean difference in BMI between
cases and controls). The following formula was used to obtain an approximate odds ratio
(OR) of the effect of BMI on psoriasis, as previously demonstrated by Perry and colleagues
[17]:
OR ¼ expð1:81� ½SD� SMD�Þ
such that SD is the standard deviation increase in BMI per SD change in the BMI genetic
instrument (genetic risk score [GRS]), SMD is the standardized mean difference, and 1.81 is
the scaling factor used to convert SMDs to ln(ORs) [18,19] (S1 Appendix Supporting Text
A).
The meta-analysis was conducted separately for children and adults, as well as combined. A
random-effects model was used due to the inclusion of heterogeneous populations and study
designs being meta-analyzed. Egger regression was also performed to detect the presence of
publication bias.
Causal impact of body mass index on psoriasis
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SD, standard deviation; SE, standard error; SMD,
standardized mean difference; SNP, single-
nucleotide polymorphism; TNFα, tumor necrosis
factor alpha; TSLS, two-staged least squares;
TSPS, two-stage predictor substitution.
Investigating causal relationships
Study populations. Data were available for a total of 396,495 participants, including 5,676
psoriasis cases from the UK Biobank, aged between 40 and 69 years [20], and 1,076 psoriasis
cases from the third survey of the Nord-Trøndelag Health Study (HUNT; 2006–2008), aged 20
years and over [21] (Table 1). All individuals included were of European ancestry and had pro-
vided written informed consent. UK Biobank has received ethics approval from the National
Health Service National Research Ethics Service (reference 11/NW/0382; UK Biobank applica-
tion number 10074). The HUNT Study was approved by the Regional Committee for Medical
and Health Research Ethics (REC Central). Approval was also received from the Regional
Committee for Medical and Health Research Ethics in Mid-Norway (2015/586, 2015/2003).
Summary-level data were also available for 356,926 individuals of European ancestry from
published GWASs for BMI [14] (n = 322,154) and psoriasis [16] (n = 34,772).
Clinical outcomes. The BMI of UK Biobank participants was calculated from standing
height and weight measurements that were taken while visiting an assessment center. Units of
BMI are kilograms per meter squared. Individuals were defined as having psoriasis based on
their response during a verbal interview with a trained member of staff at the assessment cen-
ter. Participants were asked to tell the interviewer which serious illnesses or disabilities they
had been diagnosed with by a doctor and were defined as psoriasis cases if this disease was
mentioned. Disease information was also obtained from the Hospital Episode Statistics (HES)
data extract service in which health-related outcomes had been defined by International Clas-
sification of Diseases (ICD)-10 codes (S1 Appendix Table A).
Within HUNT, participants’ height and weight were measured and used to calculate BMI
(kg/m2). Participants were defined as psoriasis cases based on their response to a general ques-
tionnaire sent to all HUNT participants. Psoriasis cases were identified by affirmative response
to the question “Have you had or do you have psoriasis?” The diagnostic properties of the pso-
riasis question have been validated in HUNT (positive predictive value was 78%; 95% CI 69–
85) [22].
Genotyping. Genotyping of UK Biobank participants was performed with one of two
arrays (The Applied Biosystems UK BiLEVE Axiom Array [Affymetrix] and Applied Biosys-
tems UK Biobank Axiom Array). Sample quality control (QC) measures included removing
individuals who were duplicated and highly related (third degree or closer), had sex mis-
matches, or those identified to be outliers of heterozygosity and of non-European descent. Fur-
ther details of the QC measures applied and imputation performed have been described
previously [23–26].
Genotyping of the HUNT participants was performed with one of three different Illumina
HumanCoreExome arrays (HumanCoreExome12 version 1.0, HumanCoreExome12 version
1.1, and UM HUNT Biobank version 1.0). The genotypes from different arrays had QC per-
formed separately and were reduced to a common set of variants across all arrays. Sample QC
measures were similar to those applied to the UK Biobank. Related individuals were excluded
from the analysis (n = 30,256). Details of the genotyping, QC measures applied, and imputa-
tion have been described elsewhere [27].
Confounder variables. Within UK Biobank, confounders that were considered in the
current study were age, sex, smoking status, alcohol intake, and educational attainment. The
age and sex of participants were baseline characteristics determined at recruitment. The infor-
mation on age was coded and analyzed as a continuous variable, while sex was analyzed as a
binary variable.
Smoking status, alcohol intake, and educational attainment were defined by responses to a
touchscreen questionnaire. The smoking status of participants was summarized as being a
Causal impact of body mass index on psoriasis
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current, previous, or never smoker, and this information was coded into a categorical variable.
Alcohol intake frequency was determined by asking participants “About how often do you
drink alcohol?” for which options included “Daily or almost daily,” “Three or four times a
week,” “One to three times a month,” “Special occasions only,” and “Never.” This information
was categorized for daily, weekly, and monthly alcohol intake. Educational attainment was
also defined by asking “Which of the following qualifications do you have?” for which partici-
pants could select more than one option, including “College or University degree,” “A levels/
AS levels or equivalent,” “O levels/GCSEs or equivalent,” “CESs or equivalent,” “NVQ or
HND or HNC or equivalent,” “Other professional qualifications, e.g., nursing, teaching,” or
“None of the above.” Participant responses were coded into categorical variables for degree
holders, as well as for those who had completed advanced-level studies (A-level) or had
obtained their general certificate of secondary education (GCSE).
Within HUNT, confounders considered in the current study were age, sex, smoking status,
and alcohol intake. Information on educational attainment was not available in the third sur-
vey of the HUNT Study. The age and sex of participants were determined at the time of partici-
pation. The information on age was coded and analyzed as a continuous variable, while sex
was analyzed as a binary variable.
Smoking status and alcohol intake were defined by the participants’ response to a question-
naire. Smoking status was defined as being never, former, occasional, or current smoker. Alco-
hol intake frequency was determined by asking participants “About how often in the last 12
months did you drink alcohol?” for which options included “4–7 times a week,” “2–3 times a
week,” “about once a month,” “a few times a year,” “not at all last year,” and “never drunk
alcohol.”
Observational analysis. Within the UK Biobank and HUNT data sets, logistic regression
models were used to estimate the observational association between BMI and psoriasis. Analy-
ses were adjusted for age, sex, smoking status, alcohol intake, and educational attainment
(where information was available in UK Biobank only). The estimates for each data set were
meta-analyzed assuming a fixed-effect model.
Defining genetic instruments. The genetic instrument for BMI comprised the 97 BMI-
associated single-nucleotide polymorphisms (SNPs) reported by the GIANT consortium to
account for approximately 2.7% of BMI variation (a meta-analysis of 125 GWASs with 339,224
individuals) [14]. These SNPs were extracted from both the UK Biobank and HUNT data sets
(S1 Appendix Table B and C) to perform one-sample MR analysis in each data set. We also
combined these SNPs to create a standardized GRS using the --score command in PLINK
(version 1.9). In doing so, the dosage of the effect allele for each SNP was weighted by the effect
estimates reported for the European sex-combined analysis (n = 322,154) by Locke and col-
leagues [14], summed across all variants, and divided by the total number of variants. The
scores were standardized to have a mean of 0 and an SD of 1.
Table 1. Descriptive statistics of data sets used in the study.
Data set Sample size Psoriasis cases/controls (% of cases) Females (%) Mean (SD) age (years) Mean (SD) BMI (kg/m2)
UK Biobank 378,274 5,676/372,598 (1.5%) 203,912 (53.9%) 57.2 (8.0) 27.4 (4.8)
HUNT 18,221 1,076/17,145 (5.8%) 10,076 (55.3%) 53.7 (15.2) 27.2 (4.4)
BMI GWAS [14] 322,154 - - - 27.1 (4.6)
Psoriasis GWAS [16] 34,772 13,229/21,543 (38.0%) - - -
Abbreviations: BMI, body mass index; GWAS, genome-wide association study; HUNT, the Nord-Trøndelag Health Study; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1002739.t001
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The BMI-associated SNP rs12016871 was not present within the UK Biobank and HUNT
data sets, therefore rs9581854 was used as a highly correlated proxy (r2 = 1.0) (S1 Appendix
Table D).
The BMI-associated SNPs most recently reported by Yengo and colleagues [15] were also
used as an updated genetic instrument for BMI.
For the psoriasis genetic instrument, 62 psoriasis-associated SNPs (outside of the human
leukocyte antigen [HLA] region) were obtained from the most recent psoriasis GWAS (a
meta-analysis of 13,229 cases and 21,543 controls of European ancestry) [16]. These SNPs
were extracted from both the UK Biobank and HUNT data sets and were used as instruments
to perform one-sample MR analysis in each data set. These SNPs were also combined to create
a standardized GRS, in which they were weighted by their published effect sizes. The psoriasis-
associated SNP rs118086960 was not present in the UK Biobank or HUNT data sets and had
no suitable proxy (r2 > 0.8). Therefore, 61 independent SNP associations were used as a
genetic instrument to perform the one-sample MR analysis (S1 Appendix Table E and F).
The reported BMI-associated SNPs and psoriasis-associated SNPs were also used to per-
form two-sample MR analysis, using summary data from the published GWAS for each trait
[14,16].
MR analysis. One-sample MR analysis was performed separately in UK Biobank as well
as the HUNT data set, using individual-level data with participants’ BMI SNPs, measured
BMI, and disease outcome status (Fig 1). The MR estimates from each genetic instrument
(SNP) were meta-analyzed assuming a random-effects model, giving a single estimate for the
analysis performed in each data set. A random-effects model was used here, to avoid overpreci-
sion of the causal estimate and to allow for heterogeneity in the causal estimates being meta-
analyzed from the different genetic variants.
The MR analysis with the individual BMI SNPs was performed with the two-stage predictor
substitution (TSPS) method [28]. The first stage involved regression of BMI upon individual
BMI SNPs. The outcome (psoriasis) was then regressed upon the fitted values from the first
regression stage. Because psoriasis is a binary outcome, the first-stage linear regression was
restricted to individuals who were controls for psoriasis only, as recommended by Burgess and
colleagues [29]. Logistic regression was then performed in the second stage, in which the fitted
values for the cases were predicted. The standard errors (SEs) of these estimates were adjusted
using the first term of the delta method expansion for the variance of a ratio, allowing for the
uncertainty in the first regression stage to be taken into account [29].
Genetic principal components (as previously described [25–27]) were included as covari-
ates in the analysis to control for residual population structure. The UK Biobank analysis also
controlled for the platform used to genotype the samples. In the HUNT data set, the genotyped
data were reduced to a common set of variants across all platforms before imputation.
Two-sample MR analysis of published GWAS data was performed using the “Mendelian-
Randomisation” R package [30,31]. Estimates for the association between BMI and BMI SNPs
in Europeans were taken from the GIANT BMI GWAS published by Locke and colleagues
[14]. Summary statistics from the most recent psoriasis [16] GWASs were used to obtain esti-
mates for the association of psoriasis with the BMI SNPs in Europeans. The published BMI
SNP estimates were based on an inverse normal transformation of BMI residuals on age and
age squared, as well as any necessary study-specific covariates. In unrelated individuals, residu-
als were calculated according to sex and case/control status and were sex-adjusted among
related individuals [14]. Therefore the causal estimates for the two-sample analysis were con-
verted to raw BMI units (kg/m2), assuming a median BMI SD of 4.6 kg/m2 [14].
The one- and two-sample estimates were meta-analyzed assuming a fixed-effect model to
obtain an overall causal estimate, assuming no between-method heterogeneity.
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An additional two-sample MR analysis was performed in the same manner, using BMI
SNP–BMI association estimates from the more recent BMI meta-analysis by Yengo and col-
leagues, in which 716 SNPs had been reported to account for approximately 5% of the variance
of BMI [15].
Sensitivity analysis. MR-Egger regression, weighted median analysis, and the weighted
mode-based estimate (MBE) were used to investigate potential pleiotropy. SNPs that act
through a pleiotropic pathway would violate the MR assumption that the instrumental variable
has an effect upon the outcome only via the exposure being investigated and could bias the
causal estimate. The weighted median method provides a valid causal estimate if at least 50%
of the information each instrument contributes to the analysis comes from valid instruments
[32]. Likewise, the weighted MBE also provides a valid causal estimate if the largest weights are
from valid instruments [33], while the intercept from the MR-Egger regression analysis allows
the size of any pleiotropic effect to be determined [34]. MR-Egger regression gives a valid
Fig 1. Schematic representation of MR analyses. (a) BMI SNPs were used as instrumental variables to investigate the causal effect
of BMI upon psoriasis. (b) Psoriasis SNPs were used as instrumental variables to investigate the causal effect of genetic risk of
psoriasis upon BMI. Arrows indicate MR assumption such that the instrumental variable is associated with the exposure—not
associated with confounders—and only affects the outcome via the exposure. BMI, body mass index; MR, mendelian randomization;
SNP, single-nucleotide polymorphism.
https://doi.org/10.1371/journal.pmed.1002739.g001
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causal estimate under the InSIDE assumption, in which each SNP–exposure association is
independent of the direct pleiotropic effect of the SNP [34].
In addition, one-sample MR analysis was performed using the FTO SNP alone (rs1558902)
as a genetic instrument due to its strong association with BMI [35].
Because the instrumental variables used in an MR analysis are assumed to be independent
of confounders, we investigated the relationship between the BMI GRS and potential con-
founders of BMI by performing a simple regression of the confounder upon the BMI GRS.
The relationship between the FTO variant and potential confounders was also investigated.
Reverse-direction MR analysis. We also investigated the causal effect of the genetic liability
of psoriasis upon BMI (Fig 1). One-sample MR analysis was performed in UK Biobank and also
in the HUNT data set with the two-staged least squares (TSLS) method, in which psoriasis-associ-
ated SNPs were used as instruments. As with the TSPS method, this analysis involves two regres-
sion stages. Psoriasis was regressed upon the psoriasis genetic instrument; the outcome (BMI)
was then regressed upon the fitted values from the first stage regression. The one-sample MR esti-
mates from each data set were then meta-analyzed assuming a fixed-effect model to give a single
causal estimate (change in BMI per log odds of psoriasis). In addition, one-sample MR analysis
was also performed such that the exposure (genetic liability of psoriasis) was considered a linear
variable with values from 0 to 1 to aid interpretation of the causal estimate (difference in BMI
between psoriasis cases and controls) (S1 Appendix Supporting Text B). Two-sample MR analysis
was also performed using the “MendelianRandomisation” R package [31] with summary results
from GWASs for psoriasis [16] and from the GIANT BMI GWAS [14]. The one- and two-sample
MR estimates were meta-analyzed using a fixed-effect model to give a final causal estimate. For
the sake of interpretation, the estimates obtained were multiplied by 0.693 to represent the change
in BMI per doubling in odds of psoriasis, as demonstrated by Gage and colleagues [36].
Sensitivity analyses were performed with MR-Egger regression, weighted median, and
weighted MBE methods. A separate two-sample MR analysis was performed in the same man-
ner, such that psoriasis SNP–BMI association estimates were extracted from the more recent
BMI meta-analysis [15].
Variants within the HLA region were not included in the genetic instrument due to the
pleiotropic nature of the region. However, two-sample MR analysis was performed using the
SNP rs13200483 alone as an instrument that tags the HLA-C�06:02 allele and is strongly asso-
ciated with psoriasis [37]. SNP estimates were taken from the most recent psoriasis GWAS
[16] and the GIANT BMI study published by Locke and colleagues [14].
All analyses were performed using R (www.r-project.org) unless otherwise stated. There
was no formal prespecified protocol for this study. The main analyses and sensitivity analyses
described above were decided on beforehand. This is with the exception of the sensitivity anal-
ysis performed with the most recent BMI meta-analysis [15], in order to demonstrate use of
the most current GWAS summary data for BMI. We also performed sensitivity analysis with a
variant at the HLA-C�06:02 locus as recommended by the reviewers. One-sample MR analyses
were also performed within UK Biobank, stratifying for psoriasis individuals who were self-
reported, or defined by the HES data extract service in response to reviewers’ comments. Fur-
thermore, publication bias was investigated for the meta-analysis of previously reported stud-
ies for the relationship between BMI and psoriasis as suggested by the reviewers.
Results
Literature review and meta-analysis
We identified 56 studies reporting data on the relationship between psoriasis and BMI, obesity,
or being overweight (see Fig A in S1 Appendix). A total of 35 studies that compared mean
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BMI between psoriasis cases and controls (Fig 2; S1 Appendix Supporting Text C) were
taken forward to be meta-analyzed. The meta-analysis found a mean difference in BMI
between psoriasis cases and controls of 1.26 kg/m2 (95% CI 1.02–1.51) among adults
(69,844 psoriasis cases and 617,844 controls) and 1.55 kg/m2 (95% CI 1.13–1.98) in children
(844 psoriasis cases and 709 controls). The ages of pediatric psoriasis patients ranged from 5
to 18 years. Where stated, the majority of the studies had defined adults to be those aged 18
years and older. However, a number of studies had used the age threshold of 15 years [38–
42], and one used 17 years to define adulthood [43]. For both adults and children, the
observed difference in BMI was equivalent to a 9% increase in the odds of psoriasis per 1 kg/
m2 increase in BMI. Twenty-one other studies tested for an association between BMI or
obesity traits and psoriasis using alternative models (S1 Appendix Table G). These all
reported a positive association, including two studies that reported the odds of psoriasis in
adults per 1 kg/m2 increase in BMI to be 1.09 (95% CI 1.04–1.16) [43] and 1.04 (95% CI
1.02–1.10) [38]. We detected very little evidence of publication bias in the meta-analysis (S1
Appendix Fig B).
Fig 2. Observational association between BMI and psoriasis. Meta-analysis of mean difference in BMI (kg/m2) between psoriasis
cases and controls. MD of 1.26 kg/m2 in adults is equivalent to OR of 1.092. MD of 1.55 kg/m2 in children is equivalent to OR of
1.093. BMI, body mass index; MD, mean difference; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1002739.g002
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Genetic instruments
The BMI GRS was strongly associated with BMI in UK Biobank (Beta = 0.64; 95% CI 0.63–
0.66, F-statistic = 7,091, R2 = 1.8%) and HUNT (Beta = 0.66; 95% CI 0.60–0.72, F-statistic = 422,
R2 = 2.3%) (S1 Appendix Fig C and D), providing evidence in support of the strength of this
instrument. We investigated the association between the BMI GRS and potential confounders
of BMI. Some small effects on the confounders were seen; however, the strength of association
was minimal in comparison to the association with BMI. This was also true for the FTO variant
alone, which is unlikely to have horizontal pleiotropic effects on these confounders (S1 Appen-
dix Fig E and F). The GRS derived for psoriasis was a good predictor of psoriasis in the UK
Biobank (OR = 1.55; 95% CI 1.51–1.59, F-statistic = 6,415, R2 = 2.1%) and HUNT (OR = 1.41;
95% CI 1.33–1.50, F-statistic = 340, R2 = 1.8%) data sets.
Effect of BMI upon psoriasis
Observational analysis. Higher BMI was associated with increased risk of psoriasis in
both the UK Biobank and HUNT data sets. Overall, a 1 kg/m2 increase in BMI was associated
with 4% higher odds of psoriasis (meta-analysis OR = 1.04; 95% CI 1.03–1.04;
P = 1.73 × 10−60) (Fig 3), slightly lower than that estimated from published literature.
MR. MR performed with UK Biobank, HUNT, and published GWAS data gave evidence
that higher BMI increases the risk of psoriasis. The causal estimate from UK Biobank showed
about an 8% increase in odds of psoriasis per 1 kg/m2 higher BMI (OR = 1.08; 95% CI 1.04–
1.13; P = 8.75 × 10−5). Similar causal estimates were also found when stratifying by psoriasis
cases that were self-reported and those defined with the HES data extract service (S1 Appendix
Table H). In HUNT, about a 7% increase was shown (OR = 1.07; 95% CI 0.98–1.17; P = 0.14).
The two-sample estimate from published GWAS data [14] also provided evidence of higher
psoriasis risk with increased BMI (OR = 1.10, 95% CI 1.05–1.16; P = 6.46 × 10−5) (Fig 3).
Meta-analysis of both one-sample and two-sample estimates produced an overall causal esti-
mate of 1.09 per 1 kg/m2 higher BMI (95% CI 1.06–1.12; P = 4.67 × 10−9, I2 statistic = 0.0%)
(Fig 3), consistent with the observational estimate from our meta-analysis of the published lit-
erature. This estimate suggests that, for example, an increase in BMI of 5 units from 25 to 30
would increase the risk of psoriasis by 53% (OR per 5-unit higher BMI = exp[Beta per 1-unit
higher BMI × 5]).
There was little evidence of pleiotropy in the MR-Egger regression analysis (UK Biobank
intercept = 0.00; 95% CI −0.01 to 0.01; P = 0.63, HUNT intercept = 0.00; 95% CI −0.02 to 0.02;
P = 0.96), and the sensitivity analyses all gave similar estimates (S1 Appendix Fig G and
Table I). In addition, when limiting the instrument to only the FTO SNP, a similar estimate
(although with a wider CI) was observed (OR = 1.11; 95% CI 1.04–1.19; P = 1.22 × 10−3) (S1
Appendix Fig H).
Two-sample MR analysis was also performed using the most recent, larger number of BMI
SNP estimates [15]. This gave a similar estimate to the overall causal estimate obtained
(OR = 1.10; 95% CI 1.06–1.13; P = 1.59 × 10−4).
Reverse MR analysis: Genetic liability for psoriasis upon BMI
The meta-analysis of UK Biobank, HUNT, and the two-sample data found no strong evidence
for a causal effect of the genetic risk of psoriasis on BMI (0.004 kg/m2 change in BMI per dou-
bling odds of psoriasis, 95% CI −0.003 to 0.011, P = 0.23) (Fig 4). Similarly, no strong evidence
of a causal effect was found when performing two-sample MR analysis with the variant at
HLA-C�06:02 (rs13200483) alone, (0.03 kg/m2 change in BMI per doubling odds of psoriasis,
95% CI −0.02 to 0.07, P = 0.24). Such estimates may be prone to misinterpretation if there is
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any heterogeneity of the effect within different subpopulations (e.g., effect only in a subset of
the population, such as those with psoriasis) [44]. However, we found no strong evidence for
such heterogeneity when comparing BMI variance across levels of the psoriasis genetic score
in UK Biobank. The meta-analysis of the one-sample UK Biobank and HUNT estimates also
estimated the increase in BMI in psoriasis cases compared to controls to be 0.27 kg/m2 (95%
CI −2.02 to 2.55) by treating psoriasis as a linear variable in the analysis. Because this estimate
is much smaller than the observational estimate (1.26 kg/m2) and the forward-direction MR
estimate is very consistent with the observational estimate, we conclude that the majority of
the relationship is due to a causal effect of BMI on psoriasis, rather than the other way around.
Discussion
The rising prevalence of psoriasis and obesity are important public health concerns
[3,5,37,45]. We found evidence of increased BMI having a causal effect upon occurrence of
Fig 3. Effect of BMI upon psoriasis. Meta-analysis of observational and one-sample and two-sample MR causal
estimates (using individual BMI SNPs as instrumental variables). Observational analysis in HUNT is restricted to
individuals with complete information on potential confounders. One-sample MR was performed separately in UK
Biobank and HUNT using individual-level data. Two-sample MR was performed with published GWAS summary-
level data for BMI [14] and psoriasis [16]. Estimates are given as change in odds per 1 kg/m2 increase in BMI. BMI,
body mass index; CI, confidence interval; GWAS, genome-wide association study; HUNT, the Nord-Trøndelag Health
Study; MR, mendelian randomization; SNP, single-nucleotide polymorphism.
https://doi.org/10.1371/journal.pmed.1002739.g003
Fig 4. Reverse-direction MR analysis: Genetic liability for psoriasis upon BMI. Meta-analysis of one-sample and
two-sample MR estimates (using individual psoriasis SNPs as instrumental variables). One-sample MR was performed
separately in UK Biobank and HUNT using individual-level data. Two-sample MR was performed with published
GWAS sum mary-level data for BMI [14] and psoriasis [16] Estimates represent the change in BMI (kg/m2) per
doubling odds of psoriasis. F-statistic = 6,415, R2 = 2.1% (UK Biobank); F-statistic = 340, R2 = 1.8% (HUNT). BMI,
body mass index; CI, confidence interval; GWAS, genome-wide association study; HUNT, the Nord-Trøndelag Health
Study; MR, mendelian randomization; SNP, single-nucleotide polymorphism.
https://doi.org/10.1371/journal.pmed.1002739.g004
Causal impact of body mass index on psoriasis
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002739 January 31, 2019 12 / 18
psoriasis, and the estimated effect size is of a magnitude that is likely to be clinically significant
(9% increased risk of psoriasis for 1 unit increase in BMI). Furthermore, the direction and
magnitude of effect seen is notably consistent with that seen observationally and in previous
literature. In the reverse direction, the estimate of 0.27 kg/m2 suggests much less influence of
psoriasis on an individual’s BMI. Overall, our results give evidence that the observational esti-
mates in the literature are predominantly explained by a causal effect of BMI upon psoriasis
and are not substantially impacted by unmeasured confounding, implying that excess adipos-
ity is part of the reason for some individuals developing psoriasis.
A key limitation of MR analysis is the possibility of pleiotropic mechanisms (from genetic
instrument to outcome, not via the exposure) invalidating the method. We performed various
sensitivity analyses to explore potential pleiotropic effects of the SNPs that make up the BMI
instrument. When restricting the instrument to only the FTO variant, for which there is good
understanding of the biological mechanism [35], we found the estimate from this analysis to
be consistent with the estimate using all BMI SNPs. This suggests that the causal estimates seen
are not predominantly driven by pleiotropic SNPs with alternative biological effects. This is
supported by the MR-Egger regression intercepts that were centered around zero (indicating
no directional pleiotropy among the included variants).
Our analysis has included a total of 753,421 individuals, including data from two of the big-
gest population-based studies currently available, and one of the largest published GWASs.
We have applied both one-sample and two-sample MR approaches, and the estimates from
these analyses were meta-analyzed to provide increased statistical power. The use of a strong
genetic instrument for BMI provides an additional strength to this study.
There are some likely limitations to this study. The data in our study included contempora-
neous measurements of BMI but relied predominantly on patient report or recall for the ascer-
tainment of psoriasis. This disease may follow an acute or chronic relapsing and remitting
course. We do acknowledge that the possible misdiagnosis of psoriasis, and mild sufferers
remaining undiagnosed, should be taken into account when interpreting the results of this
study, especially given the little overlap of psoriasis cases who are self-reported and also
defined with the HES data extract service in UK Biobank (S1 Appendix Table H). Our MR esti-
mate is also limited in that it only informs on the lifetime impact of higher BMI on psoriasis,
rather than the possible effect of a short-term intervention aiming to reduce BMI in clinical
practice. Furthermore, because the cohorts studied were of European ancestry, the ethnic vari-
ation of participants in the study is limited. In addition, the BMI SNPs used are a stronger
instrument for adult BMI compared to childhood BMI [46]. In further work, the separate
effects of visceral and subcutaneous fat may also be considered because these are likely to have
a greater impact upon inflammation compared to BMI alone.
Despite the large sample sizes included in the current study, the one-sample estimates still
have wide CIs (due to the relative low number of cases in population-based cohorts). Nonethe-
less, the similarity of the causal estimates found when analyzing UK Biobank, HUNT, and pre-
vious GWAS data does increase confidence in our findings. As expected with a large sample
size, we did observe some associations between the BMI GRS and potential confounders of
BMI. However, we found these to be minimal in comparison to the strength of the association
with BMI and therefore unlikely to be materially affecting the results. Nevertheless, it is impor-
tant to note the possible influences of unmeasured confounders, especially when utilizing large
data resources such as the UK Biobank.
There are various possible mechanisms linking obesity with skin inflammation due to func-
tional changes within adipose tissue as well as quantitative effects, such as the increased pro-
duction of inflammatory cytokines from adipose tissue [47]. Excess skin adipose tissue results
in pro-inflammatory cytokine and hormone secretion. Cytokines such as tumor necrosis
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factor alpha (TNFα) and interleukin 6 (IL-6) are directly implicated in the pathology of psoria-
sis and are targets for some highly effective treatments [48,49]. Leptin can increase keratino-
cyte proliferation and pro-inflammatory protein secretion, which are characteristics of
psoriasis [50], while the secretion of adiponectin, which is putatively anti-inflammatory [10],
is reduced in the obese state. The skin of obese individuals shows features of impaired barrier
function [51], while impairment in lymphatic function may delay the clearance of inflamma-
tory mediators [47]. Other mechanisms remain possible; however, these are weakly researched.
Our results, supporting a causal relationship, suggest that this area warrants further detailed
work.
Our findings suggest that approaches to the prevention and treatment of psoriasis might
come from targeting adiposity levels in addition to the immune pathways in skin. Although
our results imply that such interventions may be effective in the prevention of psoriasis, they
cannot determine that they would be effective at improving the disease course after onset.
However, our findings do suggest that this is a promising area to explore, particularly with val-
idation in a clinical trial setting to determine what magnitude of effect a particular intervention
may have. This is also supported by previous reports of weight loss improving psoriatic skin
and joint disease [52–54]. The concept of managing cardiovascular risk factors is already
included in clinical guidelines for psoriasis, where—although a strong observational relation-
ship has been found between these two traits [55]—there has so far been little genetic or epige-
netic overlap to support this [56]. In comparison, our findings provide evidence of causality
for the observational relationship between higher BMI and psoriasis. Furthermore, our data
suggest a potential to yield meaningful clinical benefits via a causal effect on skin disease. Our
findings come at a time when weight loss strategies are improving in the community, with a
variety of evidence-based interventions now emerging [57,58]. We believe that the need for
further trials of weight loss at different stages of psoriasis is strengthened by our work.
Although it has not been possible to investigate in the current study, analyzing the causal effect
of BMI upon severe psoriasis or various disease subtypes will also be of clinical value. We also
note that the potential health implications of this study will be dependent upon elevated BMI
in the community being amenable to intervention.
In conclusion, our findings indicate a causal effect of BMI upon psoriasis, which carries
possible health implications. These results provide further evidence supporting the need to
effectively manage obesity in the general population as well as in patients with psoriasis.
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